ACI 2011 Life Sciences FCPA Program Agenda to Be Released Soon

Jan. 19, 2011 - PRLog -- Mark your calendars now for May 17-18, 2011 in New York City. Reserve your space now to attend the one annual event specifically dedicated to focusing on the unique FCPA and anti-corruption compliance challenges faced by the pharmaceutical, medical device and biotechnology industries.

Featuring a completely updated agenda, this year’s conference will hone in on the key areas highlighted by the U.S. DOJ as high risk exposure areas for investigation, including:

•   Foreign clinical research, including CROs, HCPs, R&D & other manufacturing operations
•   Drug and device approvals in emerging markets
•   Sales & marketing and CME activity
•   Foreign subsidiary operations

Don’t miss out on this opportunity to benchmark and network with your peers as you gain best practices for revising and updating your global compliance program in light of new government enforcement initiatives.

New for this year - Interactive Working Sessions on:

A - Life Sciences Compliance Strategies for Addressing Gifts, Hospitality and Entertainment in High Risk Markets: A Practical Guide to Understanding What You Can and Cannot Do

B – Vetting Third Parties: How to Define and Execute Systematic, Risk-Based Third Party Due Diligence for Global Life Sciences Operations

Register now at http://www.americanconference.com/pharmaFCPA.htm

# # #

About ACI: A unique organization, American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world.

Visit us at http://www.americanconference.com or on our blog at http://www.americanconference.com/blog